Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial

American Journal of Psychiatry

Volumn 154, Issue 1, 1997, Pages 37-43

  Berman, Robert M ^a   Darnell, Adam M ^b   Miller, Helen L ^b   Anand, Amit ^b   Charney, Dennis S ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PINDOLOL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE RATE; RATING SCALE; REMISSION; SYMPTOMATOLOGY;

EID: 0031022587     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.1.37     Document Type: Article

References (24)

1. Berman RM, Krystal JH, Charney DS: Mechanism of action of antidepressants: monoamine hypotheses and beyond, in Biology of Schizophrenia and Affective Disease. Edited by Watson SJ. Washington, DC, American Psychiatric Press, 1996, pp 295-368
2. Blier P, de Montigny C: Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15:220-226
3. de Montigny C, Aghajanian GK: Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978; 202:1303-1306
4. Blier P, de Montigny C, Chaput Y: Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7(6 suppl):24S-35S
5. Chaput Y, de Montigny C, Blier P: Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991; 5:219-229
6. Hjorth S, Sharp T: In vivo microdialysis evidence for central serotonin(1A) and serotonin(1B) autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol. J Pharmacol Exp Ther 1993; 265:707-712
7. Hjorth S: Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 1993; 60:776-779
8. Dreshfield LJ, Engleman EA, Perry KW, Wong DT: Potentiation of the fluoxetine-dependent elevation of extracellular 5-HT levels in hypothalamus by (-)-pindolol, an antagonist at beta-adrenergic/5-HT1A receptors, in conscious rats. Society for Neuroscience Abstracts 1995; 21:859
9. Hoyer D: 5-HT receptors: subtypes and second messengers. J Recept Res 1991; 11:197-214
10. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR: Subtype of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol 1985; 117:15-24
11. Lesch KP, Poten B, Sohnle K, Schulte HM: Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans. Eur J Clin Pharmacol 1990; 39:17-19
12. Artigas F, Perez V, Alvarez E: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51:248-251
13. Blier P, Bergeron R: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
14. Mazure CM, Nelson JC, Price LH: Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 1986; 43:451-456
15. Spitzer RL, Williams JEW, Gibbon M, First MB: User's Guide for the Structured Clinical Interview for DSM-III-R (SCID). Washington, DC, American Psychiatric Press, 1990
16. Woods SW, Charney DS, Goodman WK, Heninger GR: Carbon dioxide-induced anxiety. Arch Gen Psychiatry 1988; 45:43-52
17. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
18. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
19. Stassen HH, Delini-Stula A, Angst J: Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3:127-135
20. Tignol J: A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13(suppl 2):18S-22S
21. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S: A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87:141-145
22. Schone W, Ludwig M: A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13(suppl 2):34S-39S
23. Ferrari S, Leemann T, Dayer P: The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro. Life Sci 1991; 48:2259-2265
24. Bergeron R, Blier P: Rapid antidepressant effect of pindolol with selected antidepressant drugs, in Abstracts of Panels and Posters From the American College of Neuropsychopharmacology 33rd Annual Meeting. Nashville, Tenn, ACN, 1994, p 102